ScreenerHero

LIPO Lipella Pharmaceuticals Inc.

NAS · US · Healthcare · Biotechnology · lipella.com
0.0005USD0.00%Mkt Cap: 2310 $P/E: —

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.31K USD
Enterprise Value-1.59M USD
Revenue (TTM)389.78K USD
Gross Profit-3.08M USD
Net Income (TTM)-5.02M USD
Revenue/Share0.13 USD
Last Price0.0005 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.29
EV/Revenue-4.08
P/S0.01
P/B0.00
EPS (TTM)-2.26
EPS (Forward)-3.20
52W Range
0.00020% of range0.6410
52W High0.6410 USD
52W Low0.0002 USD
Profitability
Gross Margin-573.65%
Oper. Margin-1387.94%
EBITDA Margin0.00%
Profit Margin-935.25%
ROE-261.34%
ROA-187.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.95M USD
CapEx (TTM)—
FCF Margin-725.32%
FCF Yield-122388.92%
Net Debt-1.59M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.02
Current Ratio3.24
Quick Ratio2.89
Book Value/Sh0.32 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateNov 8, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.62M
Float4.33M
Insiders6.31%
Institutions0.00%
Short Interest
Short Ratio1.8d
Short % Float1.57%
Short % Out.1.50%
Shares Short66.94K
Short (prev mo.)121.43K
Technical
SMA 500.0036 (-86.3%)
SMA 2000.0855 (-99.4%)
Beta1.89
S&P 52W Chg16.45%
Avg Vol (30d)6.41K
Avg Vol (10d)972
Technical Indicators
RSI (14)30.3
MACD-0.0061
MACD Signal-0.0082
MACD Hist.+0.0021
BB Upper0.0006 USD
BB Middle0.0005 USD
BB Lower0.0003 USD
BB Width66.74%
ATR (14)0.0038 USD
Vol Ratio (20d)0.02x